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Abstract Introduction
Jejunal self-filling blind loops with subsequent small bowel bac-
terial overgrowth (SBBO) induce hepatobiliary injury in geneti-
cally susceptible Lewis rats. Lesions consist of portal tract in-
flammation, bile duct proliferation, and destruction. To deter-
mine the pathogenesis of SBBO-induced hepatobiliary injury,
we treated Lewis rats with SBBO by using several agents with
different mechanisms of activity. Buffer treatment, ursodeoxy-
cholic acid, prednisone, methotrexate, and cyclosporin A failed
to prevent SBBO-induced injury as demonstrated by increased
plasma aspartate aminotransferase (AST) and elevated histol-
ogy scores. However, hepatic injury was prevented by mutano-
lysin, a muralytic enzyme whose only known activity is to split
the ft 14 N-acetylmuramyl-N-acetylglucosamine linkage of
peptidoglycan-polysaccharide (PG-PS), a bacterial cell wall
polymer with potent inflammatory and immunoregulatory prop-
erties. Mutanolysin therapy started on the day blind loops were
surgically created and continued for 8 wk significantly dimin-
ished AST (101±37 U/liter) and liver histology scores
(2.2±2.7) compared to buffer-treated rats (228±146 U/liter,
P < 0.05,8.2±1.9, P < 0.001 respectively). Mutanolysin treat-
ment started during the early phase of hepatic injury, 16-21 d
after surgery, decreased AST in 7 of 11 rats from 142±80 to
103±24 U/liter contrasted to increased AST in 9 of 11 buffer-
treated rats from 108±52 to 247±142 U/liter, P < 0.05. Mu-
tanolysin did not change total bacterial numbers within the
loop, eliminate Bacteroides sp., have in vitro antibiotic effects,
or diminish mucosal PG-PS transport. However, mutanolysin
treatment prevented elevation of plasma anti-PG antibodies
and tumor necrosis factor-a (TNFa) levels which occurred in
buffer treated rats with SBBO and decreased TNFa production
in isolated Kupffer cells stimulated in vitro with PG-PS. Based
on the preventive and therapeutic activity of this highly specific
muralytic enzyme, we conclude that systemic uptake of PG-PS
derived from endogenous enteric bacteria contributes to hepato-
biliary injury induced by SBBO in susceptible rat strains. (J.
Clin. Invest. 1992. 90:1313-1322.) Key words: bacterial cell
wall polymers * Kupffer cells * muramidase - peptidoglycan-po-
lysaccharide * sclerosing cholangitis - tumor necrosis factor
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We previously reported that inbred Lewis and Wistar rats with
experimental small bowel bacterial overgrowth (SBBO)' de-
velop hepatobiliary injury, but Buffalo and Fischer rats with
identical bacterial concentrations fail to exhibit hepatic inflam-
mation (1-4). SBBO rapidly develops after surgical creation of
jejunal self-filling blind loops (SFBL), which contain a com-
plex milieu ofpredominantly anaerobic enteric bacteria, bacte-
rial products such as endotoxin (lipopolysaccharide, LPS), for-
mylated oligopeptides (FMLP) and peptidoglycan-polysaccha-
ride (PG-PS), deconjugated bile salts, and other potentially
toxic metabolites. Previous studies indicated that bacterial in-
fection of liver, spleen, peritoneum, cardiac blood, and portal
vein blood did not occur (1) . Translocation ofbacteria to mes-
enteric lymph nodes was frequent in both susceptible and resis-
tant rat strains with SBBO, but did not correlate with develop-
ment of hepatobiliary injury (1). Anaerobic bacteria or their
products were incriminated in the pathogenesis of this model
by prevention of experimental hepatobiliary inflammation
with metronidazole and tetracycline (2). Gentamicin and poly-
myxin B failed to prevent injury indicating that gram-negative
aerobic organisms and LPS were not likely the cause (2).
The present study is designed to determine the mechanism
by which jejunal overgrowth ofanaerobic bacteria causes hepa-
tobiliary injury in susceptible rat strains. One possible mecha-
nism is derived from the observation that SBBO produces ab-
normal bile acids which may be toxic to the liver (5). Urso-
deoxycholic acid diminishes hepatic injury as measured by
serum enzymes in a variety ofcholestatic liver diseases presum-
ably by its effect on the bile salt pool (6). Alternatively, to
probe for a possible immune-mediated mechanism of disease,
we used cyclosporin A, prednisone, and methotrexate treat-
ment ofrats with SBBO. A third potential mechanism involves
toxic, immunogenic, persistent bacterial products derived
from the intestinal lumen. The inability ofpolymyxin B, which
binds LPS (7), to prevent hepatobiliary injury (2) provides
evidence that bacterial LPS does not play a major role in the
pathogenesis ofinjury. Other bacterial cell wall polymers, how-
ever, such as PG-PS have immunomodulating and pro-inflam-
matory properties (8) that make them logical candidates to
contribute to hepatobiliary inflammation associated with ex-
perimental SBBO.
1. Abbreviations used in this paper: AST, aspartate aminotransferase;
BHI, brain-heart infusion; GBSS, Gey's balanced salt solution; PG-PS,
peptidoglycan-polysaccharide; PG-APS, PG-PS purified from group A
streptococci; SBBO, small bowel bacterial overgrowth; SEBL and
SFBL, self-emptying and self-filling blind loops; TNFa, tumor necrosis
factor-a.
Mutanolysin in Hepatobiliary Injury Prevention 1313
J. Clin. Invest.
© The American Society for Clinical Investigation, Inc.
0021-9738/92/10/1313/10 $2.00
Volume 90, October 1992, 1313-1322
PG-PS polymers are ubiquitous in the distal intestinal lu-
men in that they are a structural component of cell walls of
nearly all bacteria including the normal intestinal flora. The
structure of PG from most bacteria is essentially similar, al-
though there are important differences in detail and immuno-
dominant epitopes (8, 9). We have utilized the PG-PS purified
from group A streptococci (PG-APS) as our standard cell wall
preparation in studies of host response to defined bacterial cell
wall polymers. Systemic injection ofPG-APS produces hepatic
granulomas ( 10), chronic erosive polyarthritis ( 1 1), and uvei-
tis ( 12) in genetically susceptible rats, whereas subserosal (intra-
mural) injection of PG-APS produces chronic spontaneously
relapsing enterocolitis with hepatic granulomas, arthritis, and
anemia (13). PG-PS derived from normal enteric flora also
can cause chronic joint ( 14, 15) and intestinal inflammation.
Rats with experimental SBBO have elevated plasma and lu-
minal anti-PG antibodies compared with sham-operated rats
and rats with self-emptying blind loops (SEBL), which serve as
surgical controls (3). After instillation of PG-APS into the je-
junum, PG-APS absorption and hepatic accumulation of PG-
APS is increased in rats with SBBO compared to sham-oper-
ated controls (3). Previous studies showed that PG-APS is con-
centrated within Kupffer cells, where it remains for at least 3
mo after intraperitoneal injection ( 16). Together, these data
indicate that PG-PS can be absorbed from the intestinal lumen
and be deposited in the liver and indirectly incriminate PG-PS
from luminal bacteria in the pathogenesis of hepatobiliary in-
flammation associated with SBBO. We hypothesize that PG-
PS derived from anaerobic bacteria proliferating within the
blind loop is absorbed, transported to the liver, and phagocy-
tosed by the Kupffer cells which then produce proinflamma-
tory cytokines, such as tumor necrosis factor-a (TNFa) and
other mediators leading to hepatobiliary injury in genetically
susceptible rats.
PG-PS polymers from certain bacterial strains, for exam-
ple, group A streptococci, are highly resistant to degradation by
lysozyme (17-19) and therefore persist within macrophages
for long periods oftime ( 16). This may explain the chronicity
of inflammation induced by certain forms of PG-PS such as
PG-APS. Easily degradable PG-PS polymers induce less
chronic inflammation ( 17-19). Mutanolysin, an enzyme de-
rived from Streptomyces globisporus, splits the ,3 1-4 linkage of
N-acetylmuramyl-N-acetylglucosamine in the glycan back-
bone of the PG-PS polymer, a linkage which is highly con-
served among bacterial species (8, 20). This muralytic enzyme
has the same specificity as tissue lysozyme but has a wider
range of activity among PG-PS from bacterial strains resistant
to lysozyme, such as PG-APS ( 17-19). After in vitro or in vivo
degradation of the PG-PS polymer by mutanolysin, chronic
inflammation is not sustained. Mutanolysin abrogated the
chronic arthritis, granulomatous hepatitis (21 ), and enteroco-
litis (22) induced by PG-APS. Because the only known func-
tion ofmutanolysin is to cleave the ,B 1-4 linkage ofpeptidogly-
can, this molecule is used in the present study as a tool to
directly study the role ofendogenous PG-PS derived from nor-
mal intestinal flora in the pathogenesis of hepatobiliary injury
associated with SBBO. This muralytic agent is compared with
ursodeoxycholic acid and several immunosuppressive agents
in prevention of hepatobiliary inflammation to define patho-
genic mechanisms in this model.
Methods
Surgical procedures. 10-cm SFBL were created in the jejunum 8-10
cm distal to the ligament of Treitz in an antiperistaltic direction using
sterile technique and ether anesthesia as described previously (23).
SBBO develops within 1 wk, rapidly reaching 108`- predominantly
anaerobic bacterial organisms per milliliter of luminal contents after
SFBL surgery (24). Surgical controls consisted of sham-operated rats
that had a laparotomy but no intestinal anastomosis and rats with
SEBL in which the loops were constructed in an isoperistaltic fashion
to empty continuously (1). Although rats with SEBL have a slight
increase (2-3 logs CFU/ml) in bacteria, manifestations of SBBO do
not develop (24).
Experimental design. Inbred female Lewis rats (Charles River
Breeding Laboratories, Raleigh, NC) weighing 150-175 g were used
because they develop hepatobiliary injury within the shortest time pe-
riod (only 3-8 wk) after experimental SBBO compared with other rat
strains examined to date ( ). After an overnight fast, SFBL were con-
structed and drug treatments were started according to the following
protocol. Groups of 6-10 rats received one of the following drugs dis-
solved in their drinking water beginning 24 h after surgery and continu-
ing until the end of the experiment: cyclosporin A (Sandoz Inc., East
Hanover, NJ; 15 mg/kg per d), prednisone (Smith Kline & French,
Philadelphia, PA; 2mg/kg per d), or methotrexate (Lederle Laborato-
ries, Wayne, NJ; 0.075 mg/kg three times per week). Drugs were
added daily to a 50-ml volume so that consumption of 20 ml would
contain an entire daily dose. The volume ofdrinking water consumed
was monitored and rats drank 20-30 ml daily. Ursodeoxycholic acid
(CIBA-Geigy Corp., Summit, NJ; 15 mg/kg per d) was given daily by
gavage feeding in a 1.5-ml volume. Cyclosporin A (Sandoz Inc.) was
also given i.m. 20 mg/kg per d using a dose previously shown to pre-
vent PG-APS-induced systemic inflammation (25). Mutanolysin
(Sigma Chemical Co., St. Louis, MO) was administered intravenously
by tail vein, 200 Mg in 200 ul ofbuffer three times per week in groups of
4-1 1 rats starting (a) within 24 h ofSFBL surgery continuing for 4 or 8
wk to determine its ability to prevent hepatobiliary inflammation, (b)
16-21 d after SFBL surgery continuing for 8-10 wk to measure its
therapeutic efficacy in early hepatobiliary inflammation, (c) 33-53
days after SFBL surgery continuing for 8-10 wk to determine its ability
to reverse advanced hepatobiliary injury. Mutanolysin was dissolved in
0.1 M potassium phosphate buffer, pH 6.2, and frozen in aliquots of 1
mg/ml solution which were used within 3 d. Control rats were treated
with 200 of0.1 M potassium phosphate buffer, pH 6.2, or heat-inac-
tivated mutanolysin. Heat-inactivated mutanolysin was boiled for 15
min immediately before use (20) and confirmed to be inactive by lack
of degradation of sonicated PG-APS over 48 h as measured by lack of
change of optical density at 600 nm.
All rats were weighed weekly. When rats were killed, cardiac blood,
peritoneal cavity fluid, liver, spleen, and mesenteric lymph nodes were
anaerobically cultured as described below. Specimens of liver were
fixed in I0% buffered formalin, then processed for histological examina-
tion and stained using hematoxylin and eosin and periodic acid-Schiff
diastase-digested techniques. Blood was drawn from the tail vein before
surgery, periodically throughout the experiments and by cardiac punc-
ture when rats were killed to measure plasma aspartate aminotransfer-
ase (AST) and TNFa.
Histologic score. Histologic slides were interpreted by one observer
in a blinded randomized manner using a system of five parameters
which was previously described (1). Normal histology scores are 0-4
and abnormal histology scores are 5-11.
Bacterial culture oforgans. A modification ofthe technique used by
Berg (26) was used as described previously ( 1-3). By using sterile in-
struments, the abdominal cavity was opened, and a peritoneal culture
was obtained by swabbing the viscera with a sterile cotton-tipped appli-
cator stick. Specimens of liver, spleen, and mesenteric lymph nodes
were excised, weighed, and homogenized using 0.4-0.7 g/ml ofbrain-
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heart infusion (BHI) for liver and spleen and 0.04-0.07 g/ml ofBHI for
mesenteric lymph nodes. All specimens were inoculated on prereduced
BHI agar plates which were cultured anaerobically in BBL Gas Pak Jars
(Becton Dickinson & Co., Cockeysville, MD) at 370C for at least 72 h.
Bacterial cultures ofluminal contents. As previously described ( 1),
10 ml of iced saline was flushed through the loop. The fluid was col-
lected, homogenized, diluted serially in BHI from 10'- to 10-10, and
cultured anaerobically.
Blind loop contents were isolated from rats treated with mutanoly-
sin in order to confirm the presence of Bacteroides sp. Blind loop con-
tents were initially diluted serially from 10'- to 10 10 and then cultured
on phenyl ethyl alcohol plates. These plates inhibit the growth ofEsche-
richia coli and other coliform species and increase the recovery ofBac-
teroides sp. After 72 h, individual colonies from plates with dilutions
l0-7 to 10 10 were subcultured both aerobically and anaerobically.
After another 72-h incubation, obligate anaerobes were gram stained.
All obligate anaerobic gram negative rods were subsequently identified
using the Minitek system (Becton Dickinson & Co.).
To directly test for a possible antibiotic effect of mutanolysin, en-
teric bacteria from six different rats were cultured in the presence and
absence ofmutanolysin. 100 Mg ofmutanolysin in a IO-Ml volume or 10
,Ml of saline alone, were added directly to aliquots ofblind loop contents
diluted l0-7 to 10-°0 as they were spread onto BHI culture plates. BHI
agar plates were cultured anaerobically for at least 72 h and colony-
forming units were counted in each group.
Anti-PG antibodies. Anti-PG IgA, IgG, and IgM antibodies were
assayed by ELISA in plasma samples taken before surgery and when
rats were killed. Formamide-extracted PG was purified from Strepto-
coccus pyogenes group A, type 3, strain D58 as previously described
(27) and microtiter wells were coated with 2 Mg/ml in phosphate-buf-
fered saline (PBS). After incubation for 15 h at 4VC, microtiter wells
were washed three times with PBS-Tween (0.5%). After unbound sites
were blocked with 0.5% bovine serum albumin, samples or immuno-
globulin standards were incubated for 8 h at 25°C. Subsequently, affin-
ity-purified anti-rat IgG or IgM antibody, which was conjugated to
alkaline phosphatase (Sigma Chemical Co.), was applied for 15 h at
4°C. Affinity purified anti-rat IgA and anti-rat-IgA conjugated to al-
kaline phosphatase were prepared as described below. Color developed
in the presence ofap-nitrophenyl substrate (tablets [ 5 mg/ml]; Sigma
Chemical Co.) and the results were read with an ELISA reader at an
optical density of405 nm. The standard curve for IgA ranged from 0 to
15 ng/ml, for IgG from 0 to 25 ng/ml, and for IgM for 0 to 500 ng/ml;
and color reaction time was 90 min.
Preparation ofanti-rat IgA and the alkalinephosphatase conjugate.
To produce affinity-purified anti-rat IgA, rat IgA was purified from
bile in order to create an affinity column. Rat bile was collected on ice
in the presence of 5 mM sodium EDTA, 500 KIU/ml aprotinin, and
0.5 mM phenylmethylsulfonyl fluoride. A 20-ml sample of bile was
loaded onto a Sephadex G-75 column ( 116 X 2.2 cm), and eluted with
PBS. The void volume fraction was applied to a Sepharose 6B column
( 1 16 x 2.2 cm) and eluted with PBS. IgA fractions were identified by
immunodiffusion, pooled, and concentrated to 5 ml. This was chro-
matographed on diethylaminoethyl cellulose-52 (DEAE-52) using a
stepwise NaCl gradient. The 0.15 M NaCl fraction contained purified
secretory IgA.
Approximately 10 mg of purified IgA were bound to a Reacti-Gel
affinity column (Pierce Chemical Co., Rockford, IL) and 0.5 ml of
reconstituted goat anti-rat IgA serum (Organon Teknika, West Ches-
ter, PA) was applied to the column. After washing the column with 10
bed volumes of PBS, the affinity-purified antibody was eluted with 35
ml ofHC1 glycine, pH 2.0. The affinity-purified antibody was dialyzed
against PBS and stored at 4°C. An aliquot of affinity-purified goat
anti-rat IgA was conjugated to alkaline phosphatase (VII-S bovine,
Sigma Chemical Co.) using glutaraldehyde (28).
Absorption ofPG-PSpolymersfrom blind loops. Intraluminal injec-
tions of PG-APS were performed in rats 4 wks after surgery. Three
groups of five rats each were tested including (a) sham-operated rats,
(b) rats with SFBL treated with intravenous buffer (0.1 M potassium
phosphate, pH 6.2), and (c) rats with SFBL treated with intravenous
mutanolysin given 200Mgg three times per week beginning 24 h after the
blind loop surgery. 4 wk after surgery, rats were anesthetized, a laparot-
omy was performed, the blind loop or corresponding proximal je-
junum was identified and 3,000 Mg of rhamnose PG-APS was injected
in a l-ml volume followed by 1 ml of saline. The injection site was
sealed with Krazy Glue (Jadow & Sons, New York). The abdominal
wall was closed and tail vein plasma samples were collected serially
every 3 h for 42 h. Subsequently, plasma was assayed for PG-APS using
ELISA (29). Mutanolysin was not given after intraloop injection.
When rats were killed, the liver was removed, and 0.5-1.0 g liver was
homogenized in 0.1 M Tris - 0.1% Tween 20, pH 8.0 (1 g wet weight
per 4 ml of buffer) and assayed for PG-APS by ELISA.
Preparation ofpurified PG and PG-APS. The culture of bacteria
and purification ofPG-APS and PG from group A, type 3, strain D-58
streptococci was done by standard procedures which have been most
recently described by Stimpson and Schwab (27).
Measurement of TNFa and AST. Blood was collected in EDTA
(1.5 mg/ml) and aprotinin (0.67 TIU/ml) (Sigma Chemical Co.),
centrifuged to collect plasma, and then stored at -70'C until assayed.
TNFa was measured using a mouse TNFa ELISA assay (Genzyme
Corp., Cambridge, MA). The reagents of this ELISA cross-react with
rat TNFa. TNFa is measured in the range 50-1,000 pg/ml with a
coefficient of variance of 8%. Serial dilution of rat plasma gave parallel
curves to mouse TNFa standard and recovery with addition of rat
plasma to mouse standard was 75-95% for 10 experiments. Briefly, the
assay was performed as follows. 96-well microtiter plates (Dynetech
Laboratories, Alexandria, VA) were coated with hamster anti-mouse
TNFa for 18 h. A blocking step was performed for 1 h and then samples
were added. After 18 h of incubation, goat anti-mouse TNFa was
incubated for 4 h. Donkey anti-goat IgG antibody conjugated with
horseradish peroxidase was incubated for 1 h. For the color reaction, a
5 mg O-phenylenediamine dihydrochloride tablet (Sigma Chemical
Co.) was diluted in 12.5 ml phosphate-citrate buffer and applied to the
wells. Reactions were read at optical density 450 after 5 min using an
ELISA reader. All incubations, except the first, were at 250C and plates
are washed five times between each incubation step.
The AST was measured in the clinical chemistry laboratory at Uni-
versity of North Carolina Hospitals by Seargen RA 1000 adaptation
(Technicon, Tarrytown, NY) using PSP activation.
Kupifer cell isolation and in vitro culture. Kupffer cells were isolated
from rat livers using a modification of the technique described by
Knook and Sleyster (30). Rat livers were perfused in the intact animal
by Krebs-Ringer-Heinsleit buffer for 5 min to remove blood. Then
0.025% collagenase (Boehringer-Mannheim Biochemicals, Indianapo-
lis, IN) perfusion was performed in Gey's balanced salt solution
(GBSS) until the liver softened (- 20 min). Perfusions were per-
formed using oxygenated solutions kept at 37°C. Oxygen consumption
was continuously monitored as a check for liver tissue viability.
After collagenase perfusion, the liver was raked with a steel comb in
order to disperse cells, which were then centrifuged at 50 g for 2 min.
Hepatocytes formed a pellet; the supernatant, which consisted of non-
parenchymal cells (Kupffer cells and endothelial cells), was saved. The
hepatocyte pellet was washed three times more in GBSS; supernatants
were pooled and made up to 15 ml which were loaded into a model
J2/21ME centrifugal elutriator (Beckman Instruments, Inc., Palo
Alto, CA). The rotor (Beckman JE-6B) speed was 2,500 rpm at 4°C
and cells were elutriated at 10, 18, 21, 36, 42 ml/min with GBSS
buffer. The purified Kupffer cell fraction was collected at 36 ml/min.
Approximately 20-40 X IO Kupffer cells were collected from a single
liver. Cells were 98% viable using trypan blue and 75% stain with per-
oxidase on cytospin preparations. These cells readily phagocytosed fluo-
rescent beads and released acid phosphatase and cathepsin.
Kupffer cells were cultured in 96-well microtiter plates (Falcon
Plastics, Becton Dickinson & Co., Lincoln Park, NJ) in RPMI 1640
with 10% low endotoxin fetal calfserum (FCS) at 370C in 5% CO2 at 2
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x 106 cells per ml. After 48 h, culture media was changed and the
following were added: culture medium alone; endotoxin (LPS from E.
coli serotype 055:B5, Sigma Chemical Co.) 1 Mg/ml; or PG-APS 40MAg
rhamnose/ml. After 8 h of incubation, supernatants were frozen and
stored at -70°C for later measurement ofTNFa. In some experiments,
1,000 ,g ofPG-APS was preincubated with 200 Mg of mutanolysin for
36 h at 37°C. < 10 pg/ml ofendotoxin were detected (as measured by
Limulus amebocyte lysate assay) in RPMI culture media with FCS,
PG-APS, and GBSS.
Statistical analysis. Comparison of luminal bacterial counts, body
weights, plasma antibody levels, in vitro TNFa levels, AST, and histo-
logic scores were performed by using the two-tailed Student's t-test.
Incidences of culture-positive mesenteric lymph nodes and rates of
spontaneous deaths were compared by using x2-
Results
Effect ofmutanolysin on hepatobiliary inflammation and clini-
cal parameters. Plasma AST levels and histology scores were
significantly lower in rats that received mutanolysin treatment
beginning 24 h after creation ofSFBL compared with rats with
SFBL that received only buffer and were not significantly dif-
ferent from sham-operated and rats with SFBL (Table I). Dur-
ing the first experiment, which terminated 4 wk after surgery,
there were 0 of 8 spontaneous deaths in the mutanolysin-
treated group compared with 44% (4 of 9) of rats with SFBL
that received buffer treatment, despite no difference in luminal
concentration ofanaerobic bacteria between mutanolysin- and
buffer-treated groups (Table I). Heat-inactivated mutanolysin
Table . Effect ofMutanolysin, Ursodeoxycholic Acid, Methotrexate,
on Prevention ofSBBO-induced Hepatobiliary Injury in Rats
used for 4 wk failed to prevent hepatobiliary injury, weight loss,
and death (Table I). The second experiment, using continuous
treatment (3 d/wk) with mutanolysin for 8 wk, confirmed that
mutanolysin prevented hepatobiliary injury as manifested by
plasma AST and hepatic histology. There were 0 of6 spontane-
ous deaths in the mutanolysin-treated group compared with
the simultaneously buffer-treated group which had 3 of 6
deaths, and treated rats gained weight rather than lost weight
(Table I). The death rate ofpooled data from rats treated with
mutanolysin for 4 or 8 wk was 0 of 14 compared with 12 of 23
(52%) in rats treated with buffer or heat-inactivated mutanoly-
sin, x2 = 8.56, P < 0.005.
As reported previously ( 1-3) and confirmed in this study,
rats with SEBL had luminal anaerobic bacterial counts of I0O
organisms per milliliter, developed no elevation of plasma
AST, and had normal histology scores. Rats with SFBL treated
with cyclosporin A (oral and i.m.), prednisone, methotrexate,
and ursodeoxycholic acid for 4 wk had 109-' organisms per
milliliter in the blind loop, gained weight less well, had elevated
plasma AST levels, and elevated histology scores compared
with sham-operated rats, rats with SEBL and mutanolysin-
treated rats with SFBL (Table I). Treatment with mutanolysin
or any other drug had no effect on total bacterial concentra-
tions. Histology scores of rats with SFBL treated with predni-
sone, methotrexate, and cyclosporin A (oral and i.m.) were
slightly but not significantly lower than those ofrats with SFBL
treated with buffer or ursodeoxycholic acid. This suggests a
mild degree of protection from these immunosuppressive
Prednisone, and Cyclosporin A,
Days survived Luminal Weight Liver histology
Group* n Died (mean) bacteria gain AST score
logoCFU/ml g U/liter
SHAM 6 0 28±0 3.9±1 .1' 32±8' 75±1211 1.6±0.9'
SEBL 6 0 28±0 5.5±1.0' 25±12" 82±1811 2.4±1.1'
SFBL-Buft 9 4 24±5 9.3±0.4 -8±23 240±142 7.5±0.8
SFBL-Mutt 8 0 28±0 9.0±0.5 -1±16 111±32"1 2.9±1.7'
SFBL-Mut (heated)t 8 5 22±5 9.4±0.8 -27±16 183±67 7.7±1.2
SFBL-Buf5 6 3 33±15 9.1±0.4 -21±26 228±146 8.2±1.9
SFBL-Mut§ 6 0 56±0** 9.5±0.9 3±21 101±3711 2.2±2.7**
SFBL-URSO 7 0 38±11 9.6±0.7 -11±21 235±134 8.3±1.1
SFBL-MTXt 5 1 28±9 9.5±0.6 -11±26 279±150 6.2±1.1"
SFBL-PREDt 5 1 22±9 9.2±0.6 -35+171l 277±142 6.5±2.4
SFBL-CYCLOt
Enteral 10 3 27±7 9.5±0.7 -28±24 390±147 6.9±1.8
Intramuscular 8 6 20±3 9.8±0.4 -28±9 259±83 6.6±1.1
All values are mean±SD. Abbreviations: SHAM, rats with sham operation 4 wk before sacrifice; SEBL, rats with SEBL (surgical control) 4 wk
before sacrifice; SFBL-Buf, rats with SFBL treated with i.v. 0.1 M potassium phosphate buffer, pH 6.2, three times weekly; SFBL-Mut, rats
with SFBL treated with i.v. mutanolysin 200 .g per rat, three times weekly; SFBL-Mut (heated), rats with SFBL treated with i.v. mutanolysin
200 ,g per rat three times weekly for 4 wk; mutanolysin was inactivated by boiling 15 min; URSO, ursodeoxycholic acid therapy 15 Mg/kg per
d for 4 wk by gavage feeding; MTX, methotrexate 0.0 15 mg three times weekly for 4 wk in drinking water; PRED, prednisone therapy 2 mg/kg
per d for 4 wk in drinking water; CYCLO, cyclosporin A treatment 15 mg/kg per d either in drinking water or intramuscularly 20 mg/kg per d
for 4 wk. * Treatment started 24 h after surgery and continued until rats were killed. * Treatment for 4 wk three times per week. § Treatment
for 8 wk three times per week. Compared to SFBL-Buf treated for 4 wk, 11 P < 0.05; 'P < 0.001; Compared to SFBL-Buf treated for 8 wk,
** P < 0.005.
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Table II. Effect ofMutanolysin Therapy Which Was Started after
Biochemical Evidence ofSBBO-induced Hepatobiliary Injury
SFBL-Buffer* SFBL-Mutt SFBL-Mut§
Number per group 11 11 4
Weight gain (g)"1 -13±25 19+1 1tt -24±8
AST (u/liter)'
Pre-op 75±13 80±25 73±15
Pre-Rx 108±52 142±80 219±40**
End expt 247±142 103±24** 172±102§§
RX started (days
after surgery) 17±1 17±2 45±10#t
Duration of Rx (days) 16±9 45±1 It 33±21**
Death (days after surgery) 33±9 62±12tt 76±15tt
Deaths/total number (%) 5/11 (45%) 1/1 1** (9%) 2/4 (50%)
Histology score 7.1±2.4 2.6±2.0*t 6.5±1.71111
* Rats with SFBL treated with intravenous 0.1 M potassium phos-
phate buffer, three times weekly. t Rats with SFBL treated with
intravenous mutanolysin, 200 tg per rat three times weekly, starting
16-21 d after surgery. § Rats with SFBL treated with intravenous
mutanolysin, 200 Ag per rat three times weekly, starting 33-53 d after
surgery. 11 Weight gain from time of surgery. ' Plasma AST before
surgery (pre-op), before starting therapy (pre-Rx), and at the termina-
tion of the experiment (end expt). Compared to SFBL-Buffer, ** P
< 0.05; # P< 0.001; compared to SFBL-Mut, " P< 0.05; 1111 P< 0.001.
drugs although death rates and plasma AST were no different
than in rats treated with buffer. Prednisone-treated rats actu-
ally lost more weight than buffer-treated rats.
The blind loop intestinal mucosa was examined histologi-
cally by two blinded observers and no difference was found
between mutanolysin-treated groups and rats with SFBL that
received buffer or heat-treated mutanolysin. Histology con-
sisted ofthickened mucosa, muscular, and serosal layers. There










onstrated a marked mononuclear cell infiltration in the muco-
sal layer.
To determine where mutanolysin could treat as well as pre-
vent hepatobiliary injury, i.v. mutanolysin was started 16-21 d
after SFBL surgery when plasma AST was elevated (142±80
U/liter) compared to presurgical values (80±25 U/liter), P
< 0.025. Delayed treatment led to final AST and histology
scores which were significantly lower than those of rats with
SFBL treated with buffer (Table II). Rats were electively killed
42-78 d after surgery, i.e., 25-61 d after starting mutanolysin
treatment, yet hepatic histology was nearly normal. There was
one death in the group that received mutanolysin starting 16-
21 d after SFBL surgery and weight gain was 18±11 g, both
significantly better than in rats with SFBL treated with buffer. 9
of 11 buffer-treated rats demonstrated an increase in AST by
> 50 U/liter from pretreatment values and no rat had declin-
ing values. This is significantly different than mutanolysin-
treated rats ofwhich 7 of 11 had declining AST values and no
rat had an increase in AST > 50 U/liter, P < 0.001 (Fig. 1).
When i.v. mutanolysin treatment was delayed until plasma
AST values were quite elevated (219±40 U/liter at 33-53 d
after SFBL surgery), there was less protection, in 50% (2 of 4)
of the treated rats died. The two survivors were treated with
mutanolysin for 31 and 62 d before being electively killed.
Plasma AST were lower than they had been when treatment
was started and histology scores were 5 and 6 in the two surviv-
ing rats compared to historical scores of8-1 1 in rats with SFBL
for this long duration ( 1, 2). In the other two rats in this group,
AST did not improve and death occurred spontaneously in one
and by accidental ether overdose during blood collection in
another.
Bacteriology results. Cultured liver, spleen, cardiac blood,
and peritoneal swabs were negative for bacterial growth in all
rats. Mesenteric lymph nodes were culture-positive in 16% (1
of6) of rats with SEBL but were positive in 80% (8 of 10), 88%
(7 of8), 83% (15 of 18), 100% (5 of5), 80% (4 of5), 86% (6 of
7) of rats treated with buffer, mutanolysin, cyclosporin A (oral~~~~~~~~*
pro post pro p
SFBL-Buffer SFBL-Early Mutanolysin





Figure 1. Change in plasma AST with mutanolysin therapy of rats with SBBO. Individual plasma AST (units per liter) from rats were tested
before treatment was started (pre). Treatment consisted ofIV buffer (started 16-21 d after surgery, n = 11), early mutanolysin treatment (started
16-21 d after surgery, n = I 1) and late mutanolysin treatment (started 33-53 d after surgery, n = 4). AST levels were tested at the end of the
experiment (post). Mutanolysin was given i.v. 200 ,g three times per week. *Posttreatment AST values which increased > 50 U/liter compared
to pretreatment levels. 9 of 11 rats demonstrated an increase in AST of> 50 U/liter in buffer-treated rats compared to 0 of 11 rats treated with
mutanolysin beginning days 16-21, X2 = 12.03, P < 0.001.
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Figure 2. Plasma anti-PG antibody levels after mutanolysin treat-
ment. Plasma anti-PG IgA, IgG, and IgM levels drawn at the time of
surgery (open boxes) and at the end of the experiment (hatched
lines). Antibodies were measured by ELISA. Values represent
mean±SD. SHAM, sham-operated rats, n = 6. SFBL, rats with SFBL,
treated with buffer beginning the day of surgery, n = 10. SFBL-Mut
(day 0), rats with SFBL treated with mutanolysin beginning the day
of surgery, n = 12. SFBL-Mut (days 16-21), rats with SFBL treated
with mutanolysin beginning 16-21 d after surgery, n = 1 1. SFBL-Mut
(days 33-53), rats with SFBL treated with mutanolysin beginning
33-53 d after surgery, n = 4. +P < 0.05; ++P < 0.01 for levels drawn
at the end of the experiment, compared to SFBL-buffer-treated rats.
and i.m.), prednisone, methotrexate, and ursodeoxycholic
acid, respectively (X2 = 8.96, 14.70, 10.21, 11.37, 7.95, 9.29; P
< 0.005 for all relative to rats with SEBL), indicating a signifi-
cantly greater amount of bacterial translocation to mesenteric
lymph nodes in rats with SFBL regardless of treatment.
Cultures of blind loop contents in rats with SFBL showed
10'1o organisms per milliliter regardless of treatment (Table
I). Subcultures of blind loop contents revealed the presence of
Bacteroides sp. in all rats tested (6 of6) that received mutano-
lysin treatment. When 10 ,ug ( 10 ,l) mutanolysin were added
directly to dilutions of blind loop contents, no difference in
colony-forming units was detected at the dilutions tested, ( IO
to 10-10) in six rats.
Antibody in plasma specificfor PG. We have used plasma
anti-PG antibodies as an indirect indicator of luminal PG-PS
absorption (3). Plasma anti-PG IgA, IgG, and IgM antibodies
were significantly increased 4 wk after surgery in rats with
SFBL treated with buffer, or mutanolysin starting 33-53 d after
surgery; no such increase in anti-PG antibodies occurred in
rats with SFBL treated with mutanolysin beginning 0 or 16-21
d after surgery (Fig. 2). Sham-operated rats showed small but
significant elevations in anti-PG-IgG and anti-PG-IgM anti-
bodies when preoperative levels were compared to levels ob-
tained when rats were killed, indicating continued exposure to
luminal PG from normal bacterial flora and/or maturation of
the immune system. Rats treated with mutanolysin from day 0
and from days 16 to 21 had almost exactly the same anti-PG
antibody levels as sham-operated rats. Therefore, early treat-
ment with mutanolysin (before 21 d after surgery) reduced the
large elevations of anti-PG antibodies which occurred in rats
with SFBL which were treated with buffer, but delayed treat-
ment with mutanolysin beginning 33-53 d after surgery had no
effect on anti-PG antibodies or hepatobiliary inflammation.
Absorption of PG-APS after intraluminal injection. As a
more direct measure ofsystemic absorption ofPG-PS from the
SFBL, PG-APS was injected intraluminally. Because the APS
moiety is antigenically distinct from cell wall antigens of nor-
mal rat microbial flora, plasma levels of PG-APS provide a
sensitive index of absorption of exogenous luminal PG-PS.
After a single intraluminal injection, PG-APS was measured in
12 serial plasma samples taken over the next 42 h from sham-
operated rats, rats with SFBL treated with mutanolysin, or rats
with SFBL treated with buffer. The plasma levels in sham-
operated rats peaked at 6 h (18±7 ng/ml) and then rapidly
declined, but were elevated for 3-30 h in rats with SFBL with
Table III. Systemic Absorption of3,000 ,gg ofPG-APS
after Injection into the Blind Loop or Corresponding Area
ofJejunum ofSham-operated Rats 4 wk after Surgery
Expt group* Area under curvet Total liver PG-APS




Abbreviations: SFBL-Buf, rats with SFBL treated with i.v. 0.1 M po-
tassium phosphate buffer three times weekly; SFBL-Mut, rats with
SFBL treated with i.v. mutanolysin 200 Mg per rat three times weekly,
starting within 24 h of surgery and stopping 24 h before the injection
of PG-APS into the blind loop. SHAM, sham-operated rat receiving
no therapy. * Each experimental group had five rats and values are
mean±SD. * Area under the curve of a plot with plasma PG-APS
(ng/ml) on the vertical axis and time (hours) on the horizontal axis.
The values are arbitrary square units (ng/ml X time in hours). § Rats
were killed 42 h after injection of the blind loop or corresponding
jejunum and livers were removed. Liver tissue was homogenized and
assayed for PG-APS content using ELISA. Compared to SFBL-Mut,
"P< 0.05; IP< 0.025.
1318 Lichtman et al
l
or without mutanolysin treatment. Peak levels for rats with
SFBL treated with buffer were 29±11 ng/ml at 15 hand 33±14
ng/ml (mean±sd) at 15 h for rats with SFBL treated with mu-
tanolysin. Both of these values were significantly greater than
corresponding levels from sham-operated rats,P< 0.05. Signifi-
cantly elevated levels were also found at 3 and 30 h for rats with
SFBL with and without mutanolysin treatment compared with
sham-operated rats, P < 0.05; plasma PG-APS levels were con-
sistently higher in both groups with SFBL compared with
sham-operated rats. The cumulative results (as measured by
calculating the area under a curve for a graph using PG-APS
nanograms per milliliter on the vertical axis and time in hours
on the horizontal axis), from rats with SFBL with buffer treat-
ment and those with SFBL that were treated with mutanolysin,
showed significantly more absorption of PG-APS into plasma
compared to sham-operated rats (Table III). Thus, mutanoly-
sin treatment did not alter absorption of PG-APS into the
plasma (Table III). Similarly, hepatic concentrations of PG-
APS were significantly greater in rats with SFBL with or with-
out mutanolysin treatment compared to low levels found in
livers of sham-operated rats which received the same intralu-
minal dose of PG-APS (Table III). Liver homogenates from
rats which have never been injected with PG-APS contain < 2
ng/g liver (3) which is 10-fold lower than values in sham-oper-
ated rats injected with PG-APS. These data confirm that PG-
PS absorption is increased from an SFBL relative to normal
intestine (3) and show that prolonged mutanolysin treatment
did not alter mucosal permeability to these macromolecules. It
should be noted that mutanolysin therapy was stopped 1 d
before instillation of PG-APS into the lumen.
In vivo and in vitro TNFa measurements. Plasma samples
were drawn every 3-7 d after creation of SFBL in rats treated
with buffer or mutanolysin to serially measure circulating
TNFa (Table IV). Baseline values before surgery (day 0) for
six rats receiving buffer and six rats receiving mutanolysin was
61±12 pg/ml (mean±SD). A significantly elevated plasma
level was considered to be > 2 SD above the mean, (> 85 pg/
ml). The TNFa ELISA detection limits are 50 pg/ml and any
samples below detection were arbitrarily assigned a value of 50
pg/ml. In the six buffer-treated rats with SFBL, during days 3,
6, and 9 after surgery, only two plasma samples were consid-
Table IV. Plasma TNFa Levels in Rats with SBBO
with and without Mutanolysin Treatment
SFBL-Buffer SFBL-Mutanolysin
pg/ml*
Day 0 66±14 56±11
Day 3 57±8 56±8
Day 6 62±15 55±8
Day 9 80±22 61±10
Day 15 84±37 60±8
Day 18 114±30* 62±14
Day 21 101±44$ 56±7
Day 28 120±17§ 61±13
* All values are mean±SD for each group containing six rats.
For rats with SBBO treated with buffer compared to those treated
with mutanolysin, IP < 0.05, § P < 0.001.
Table V. TNFa Releasefrom Cultured Kupffer Cells*
TNF
pg/mit
KC + media alone <50
KC + LPS (l jg/ml) 311±71
KC + PG-APS (40 ,g/ml) 486±71
KC + mutanolysin-digested PG-APS5 145±44
* Kupffer cells (KC) were cultured at 2 X 106 cells/ml for 48 h before
addition of LPS, PG-APS, or mutanolysin-digested PG-APS. t Data
represent results mean±SD from four different experiments. § 1,000
jtg of PG-APS was preincubated with 200 jsg of mutanolysin at 370C
for 36 h and 40 ,g/ml PG-APS was added to Kupffer cell cultures.
ered elevated out of 18 samples but on days 15, 18, 21, and 28,
16 samples out of 24 (66%) were > 85 pg/ml. In rats with
SFBL that were treated with mutanolysin, no plasma samples
were elevated in the first 9 d after surgery and only 2 of 24
samples (8%) were elevated from days 15, 18, 21, and 28 after
surgery. The difference in elevated plasma TNFa levels be-
tween mutanolysin-treated rats with SFBL and buffer-treated
rats was significant (x2 = 16.60, P < 0.001). Table IV demon-
strates that rats with SFBL treated with mutanolysin had
plasma TNFa levels which remained at low background levels
for the duration of the experiment, in contrast to those rats
treated with buffer which increased with time. TNFa levels of
buffer-treated rats were statistically greater than mutanolysin-
treated rats at days 18, 21, and 28.
Purified Kupffer cells were cultured for 48 h and then incu-
bated with LPS, PG-APS, or mutanolysin-digested PG-APS.
Supernatants from these cultures were assayed for TNFa (Ta-
ble V). LPS (1 ug/ml) and PG-APS (40 ,g/ml) both caused
large releases of TNFa but when PG-APS was degraded by
mutanolysin, TNFa production was decreased by 75% and was
not significantly elevated above levels from unstimulated
Kupffer cells (Table V).
Discussion
Demonstration that the muralytic enzyme mutanolysin pre-
vented experimental hepatobiliary injury in rats with SBBO
supports the hypothesis that systemic absorption of endoge-
nous PG-PS from luminal bacteria causes this lesion. Because
there was no reduction of total intestinal anaerobic bacterial
counts, no elimination ofBacteroides sp. from the lumen ofthe
SFBL, and no prevention of bacterial translocation to mesen-
teric lymph nodes, we conclude that mutanolysin had no appar-
ent antibiotic properties. We directly tested this observation by
adding mutanolysin to dilutions of enteric organisms from the
blind loop and found that the number ofcolony-forming units
on culture plates was not significantly different with or without
mutanolysin. The only known biologic activity ofmutanolysin
is to split the ,B 1-4 linkage of N-acetyl muramic acid-N-acetyl
glucosamine in PG, which renders the PG-PS polymer unable
to initiate or sustain chronic inflammation (20, 2 1). Previous
studies showed that the chronicity of systemic inflammation
caused by i.p. PG-APS injection was affected by the molecular
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weight of PG-PS, in that smaller polymers (< 5 X 106 mol wt)
caused only acute inflammation while larger PG-PS fragments
caused chronic, spontaneous relapsing inflammation (31).
High molecular weight PG-APS remained in inflamed tissues
for at least 3 mo ( 16, 29) and caused chronic relapsing inflam-
mation. PG-PS from certain bacteria such as Peptostreptococ-
cus causes only transient inflammation, whereas PG-PS from
group A streptococci and Eubacteria cause chronic granulo-
matous inflammation (14, 15). These observations demon-
strate that chronicity ofinflammation induced by PG-PS corre-
lates with persistence of cell wall polymers in tissues, i.e.,
poorly biodegradable, larger polymers induce chronic inflam-
mation, but easily degradable polymers cause only acute, tran-
sient inflammation ( 1 1, 17-19). Thus, mutanolysin could pro-
tect tissues from injury by degrading PG-PS before this poly-
mer could activate immunocytes as demonstrated by the
decrease in TNFa production by Kupffer cells exposed to PG-
PS digestion with mutanolysin. Additionally, mutanolysin can
reduce injury even after inflammation has been established, as
has been demonstrated by in vivo studies with this enzyme in
models ofexogenously administered PG-PS. A single i.v. injec-
tion of mutanolysin was able to prevent chronic arthritis and
granulomatous hepatitis when given 3 d after i.p. PG-APS and
greatly reduced severity of disease even when given 14 d after
PG-APS (21). In recent preliminary studies, i.v. mutanolysin
prevented chronic enterocolitis when given at the time of sub-
serosal PG-APS injection and diminished injury even when
given up to 7 d after onset of the chronic relapsing phase of
inflammation, 21 d after PG-APS injection (22).
This study confirmsthe association ofSBBO and hepatobili-
ary injury ( 1-4) and explores mechanisms oftissue inflamma-
tion. Ursodeoxycholic acid did not prevent injury, making tox-
icity by bacterially altered bile salts unlikely. Similar doses of
ursodeoxycholic acid effectively treated liver disease caused by
bile duct ligation in rats (32) although a significant beneficial
effect on histology was not obvious (33). The possibility that
the immune response plays a major role in the pathogenesis of
hepatic injury was studied by examining the effect of metho-
trexate, prednisone, and cyclosporin A. None ofthese immuno-
suppressive drugs prevented hepatobiliary injury. Methotrex-
ate, cyclosporin A, and prednisone slightly decreased the histol-
ogy score but other parameters, such as increased plasma AST
and death rate, were not altered. Cyclosporin A has been shown
to prevent development of hepatic granulomas in rats injected
i.p. with PG-APS (25). However, those studies investigated
inflammation induced by a large single i.p. injection of bacte-
rial polymers derived from an organism not typically found in
rats. In rats with SBBO, the hepatobiliary injury may differ
from injury induced by a single i.p. bolus ofPG-APS because of
sustained exposure to endogenousbacteria which contain heter-
ogeneous PG polymers. This continuous exposure probably
results in a lower daily dose of cell wall polymers, although the
cumulative amount ofPG-PS absorbed may be large. No gran-
ulomas occur in SBBO-induced hepatobiliary injury and the
injury requires a slightly longer time to develop than the injury
that follows i.p. injection of PG-APS. Another reason for dif-
ferences between i.p. PG-APS and SBBO-associated liver dis-
ease is the source of PG-PS. Most enteric bacterial PG-PS in-
duces only transient inflammation, although some species of
normal flora bacteria produce poorly biodegradable PG-PS ca-
pable of inducing chronic granulomatous inflammation ( 13,
14). Rats with experimental SBBO are exposed to a large num-
ber of different PG-PS polymers derived from the diverse en-
teric bacterial species that proliferate within the blind loop (5).
Mutanolysin therapy could prevent hepatobiliary injury in
rats with SBBO by several mechanisms, including decreasing
absorption of PG-PS, splitting PG-PS after mucosal absorption
but before stimulation ofimmune cells, or enhancing degrada-
tion after tissue accumulation occurs. To test the effect of mu-
tanolysin therapy on intestinal absorption and immune re-
sponse, plasma anti-PG IgA, IgG, and IgM antibodies were
assayed before surgery and when rats were killed. The levels of
these antibodies increased in rats with SBBO receiving buffer
treatment but did not increase in rats with SFBL treated with
mutanolysin starting immediately after blind loop surgery or
16-21 d after surgery. However, mutanolysin treatment de-
layed until 33-53 d after SFBL surgery did not prevent eleva-
tion of anti-PG antibodies. The presence of a low baseline of
anti-PG antibodies in rats and humans has been documented
in the past (9) and indirectly reflects mucosal absorption of
antigenic PG to which normal animals are continually ex-
posed. The absence of increased anti-PG antibodies after early
initiation of mutanolysin therapy may indicate a lack of ab-
sorption from the intestine or that degradation of PG occurs
before stimulation of the humoral immune response. Elevated
anti-PG antibodies are probably of no pathogenic significance
in that they did not correlate with hepatic injury ( 1). Anti-PG
antibody levels also did not correlate with the degree ofarthritis
after i.p. injection ofPG-PS (34). They represent one measure
of absorption of PG-PS in that they were not elevated in Lewis
rats treated with metronidazole, a treatment which diminishes
PG-APS absorption after injection into the blind loop presum-
ably by decreasing mucosal injury (2). Buffalo rats, which de-
velop no hepatobiliary injury associated with SBBO although
they also develop mucosal injury ( 1, 4), displayed elevated
anti-PG IgG, IgA, and IgM (data not published). Buffalo rats
develop similar disaccharidase deficiency, similar increases in
anaerobic bacterial numbers as Lewis rats (1) and absorbed
PG-APS after intraloop injection to a similar degree as Lewis
rats. This data indicate that despite similar absorption of PG-
PS across injured mucosa of the SFBL, Buffalo rats are resis-
tant to the chronic hepatobiliary inflammation which occurs in
Lewis rats. This is consistent with previous data comparing
tissue levels of PG-APS after i.p. injections. On days 3 and 30
after i.p. injection, high responding Sprague-Dawley rats and
Buffalo rats had similar joint and hepatic concentrations of
PG-APS but the high responding rats developed chronic granu-
lomatous inflammation whereas Buffalo rats had normal histol-
ogy (35).
To directly test the effect of mutanolysin on intestinal ab-
sorption of PG-PS, uptake of PG-APS from blind loops was
compared among rats with sham-operation or with SFBL
treated with mutanolysin or phosphate buffer for 4 wk after
surgery. Serial plasma levels of PG-APS, during 42 h after in-
jection ofPG-APS into the blind loop, and liver content when
rats were killed were no different between the mutanolysin-
and buffer-treated groups and were significantly higher than
values obtained in sham-operated rats. Systemic mutanolysin
therapy also had no apparent beneficial effect on intestinal in-
flammation within the SFBL. Thus chronic parenteral mutan-
olysin treatment does not prevent absorption of PG-PS from
the intestinal lumen. This would imply that degradation of
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PG-PS by mutanolysin occurs before stimulation of the hu-
moral immune response and possibly before phagocytosis and
activation of Kupffer cells. The latter suggestion is supported
by diminished TNFa production by PG-APS digestion in
vitro using mutanolysin. We previously showed that PG-
APS extracted from liver tissue 1, 3, and 15 d after i.p.
injection was significantly degraded in rats treated in vivo with
mutanolysin ( 19).
Mutanolysin therapy diminished in vivo and in vitro TNFa
production, suggesting that TNFa may have an important role
in the pathogenesis of hepatobiliary inflammation induced by
SBBO. Mutanolysin treatment almost totally prevented in-
creased plasma TNFa levels which developed by 18 d in un-
treated rats with SBBO. We have previously shown that admin-
istration of palmitate, which blocks phagocytosis by Kupffer
cells, and pentoxifylline, which blocks TNFa secretion by
Kupffer cells, both prevented hepatic injury in rats with SBBO
(36). Therefore, mutanolysin could function in part by de-
grading absorbed PG-PS before Kupffer cell activation occurs
thereby preventing release of cytokines, prostaglandins, leuko-
trienes and other inflammatory mediators involved in hepato-
biliary injury. For example, we have recently shown that IL- 1
and the kallikrein-kinin system have a role in the pathogenesis
of chronic inflammation induced by PG-APS (37-39).
These experiments directly support previously reported in-
direct evidence that luminal PG-PS from jejunal SFBL causes
hepatobiliary inflammation. We have demonstrated that: anti-
PG antibodies are increased in rats with SBBO (3); increased
absorption of luminal PG-APS occurs in rats with SBBO (3);
hepatobiliary injury is prevented by metronidazole (2); there is
enterohepatic circulation of PG-APS (40); and inbred rat
strains have similar susceptibilities to SBBO-induced hepatobil-
iary injury as that which occurs after i.p. injection of PG-APS
which induces chronic liver granulomas (10) and arthritis
( 1). Based on these results and the present evidence that mu-
tanolysin prevents and treats hepatic injury associated with
SBBO, we conclude that PG-PS from an overgrowth ofendoge-
nous anaerobic enteric bacteria can cause chronic hepatobili-
ary inflammation in genetically susceptible rats. Previous re-
ports document the inflammatory potential ofintestinal bacte-
ria and their cell wall polymers. Stimpson et al. ( 14) showed
that purified PG-PS from normal intestinal flora was arthro-
pathogenic in rats and Severijnen et al. ( 15 ) showed that puri-
fied PG-PS from several strains of Eubacterium produced
chronic arthritis in rats after systemic injection. Subserosal in-
jections of purified PG-PS from group D streptococci cause
chronic enterocolitis (13). Normal flora bacteria, bacterial
products, and luminal PG-APS can potentiate nonspecific en-
terocolitis after acute intestinal injury (41, 42) and Lewis rats,
but not Fischer F334, with intestinal injury induced by indo-
methacin develop hepatomegaly and liver inflammation (43).
Experiments presented here show that mutanolysin, whose
only known function is to degrade PG-PS, is effective in pre-
venting and treating hepatobiliary injury associated with experi-
mental SBBO. Further work to demonstrate a role for endoge-
nous PG-PS in causing and/or perpetuating chronic inflamma-
tory diseases such as chronic inflammatory bowel disease and
its extraintestinal manifestations, especially hepatobiliary in-
flammation and arthritis, in humans is required. Potential
treatment of such diseases with mutanolysin or a derivative of
this muralytic enzyme is suggested.
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